INKT

7.17

2.31% -0.1695

Handel nachbörslich: 7.17

Mink Therapeutics Inc (INKT)

Überblick Nachrichten Preisverlauf Financials Forum Prognose

Schlusskurs vom Vortag:

$7.3395

Offen:

$7.1716

24-Stunden-Volumen:

1,376

Relative Volume:

0.27

Marktkapitalisierung:

$30.20M

Einnahmen:

Nettoeinkommen (Verlust:

$-24.77M

KGV:

-9.8219

EPS:

-0.73

Netto-Cashflow:

$-17.36M

1W Leistung:

-5.53%

1M Leistung:

+0.00%

6M Leistung:

-29.01%

1J Leistung:

-19.44%

1-Tages-Spanne:

$7.17

$7.1716

1-Wochen-Bereich:

$6.9118

$7.51

52-Wochen-Spanne:

$4.5601

$13.79

Mink Therapeutics Inc Stock (INKT) Company Profile

Firmenname

Mink Therapeutics Inc

Sektor

Healthcare (1166)

Branche

Biotechnology (655)

Telefon

212-994-8250

Adresse

149 FIFTH AVENUE, NEW YORK

Mitarbeiter

Twitter

Nächster Verdiensttermin

2024-08-13

Neueste SEC-Einreichungen

INKT's Discussions on Twitter

Vergleichen Sie INKT mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
INKT Mink Therapeutics Inc	7.17	30.20M	0	-24.77M	-17.36M	-0.73
VRTX Vertex Pharmaceuticals Inc	457.03	115.95B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	547.74	56.52B	14.09B	4.50B	2.96B	39.28
ALNY Alnylam Pharmaceuticals Inc	329.77	39.44B	2.35B	-269.70M	-75.39M	-2.09
ARGX Argen X Se Adr	545.11	35.14B	2.58B	1.06B	-1.28B	16.33
ONC Beone Medicines Ltd Adr	244.32	28.51B	3.81B	-644.79M	-669.77M	-6.24

Mink Therapeutics Inc Aktie (INKT) Neueste Nachrichten

Jun 10, 2025

Where are the Opportunities in (INKT) - news.stocktradersdaily.com

Jun 10, 2025

Kalkine: MiNK Therapeutics Sees Gains Amid Positive Earnings Per Share Momentum - Kalkine Media

Jun 10, 2025

MiNK Therapeutics Announces Virtual Annual Shareholders Meeting - Eagle-Tribune

Jun 10, 2025

MiNK Therapeutics Annual Meeting: How Shareholders Can Join Virtually on June 18 - Stock Titan

Jun 10, 2025

MiNK Therapeutics (NASDAQ:INKT) Stock Price Up 0.1% – Here’s Why - Defense World

Jun 10, 2025

Jun 03, 2025

MiNK Therapeutics receives NIH grant for GvHD therapy - Investing.com India

Jun 03, 2025

Jun 02, 2025

MiNK Therapeutics, Inc. Awards Prestigious Niaid Grant to Advance Allo-Inkt Cell Therapy for Prevention of Gvhd in Stem Cell Transplant Patients - MarketScreener

Jun 02, 2025

INKT Secures Grant for GvHD Cell Therapy Development | INKT Stoc - GuruFocus

Jun 02, 2025

MiNK Therapeutics Receives NIAID Grant to Advance Allo-iNKT Cell Therapy for Graft-Versus-Host Disease Treatment - Nasdaq

Jun 02, 2025

MiNK Therapeutics Awarded Prestigious NIAID Grant to - GlobeNewswire

Jun 02, 2025

NIH Backs Revolutionary Cell Therapy: MiNK's Solution Could Prevent Deadly Transplant Complications - Stock Titan

Jun 02, 2025

May 29, 2025

(INKT) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com

May 29, 2025

May 28, 2025

Amer Sports: The New ONON and DECK of Consumer Discretionary? - The Globe and Mail

May 28, 2025

May 19, 2025

MiNK Therapeutics outlines near-term partnering proposals and reduced cash burn as company advances iNKT programs - MSN

May 19, 2025

HC Wainwright Cuts Earnings Estimates for MiNK Therapeutics - Defense World

May 19, 2025

May 16, 2025

MiNK Therapeutics, Inc. (NASDAQ:INKT) Q1 2025 Earnings Call Transcript - Insider Monkey

May 16, 2025

MiNK Therapeutics Reports Q1 2025 Progress and Financials - TipRanks

May 16, 2025

May 15, 2025

Mink Therapeutics’ Earnings Call Highlights Progress and Optimism - TipRanks

May 15, 2025

Transcript : MiNK Therapeutics, Inc., Q1 2025 Earnings Call, May 15, 2025 - marketscreener.com

May 15, 2025

MiNK Therapeutics (INKT) Advances in Immune Response Innovation - GuruFocus

May 15, 2025

MiNK Therapeutics (INKT) Advances in Immune Response Innovation | INKT Stock News - GuruFocus

May 15, 2025

MiNK Therapeutics Reports Clinical Advancements and Financial Update for Q1 2025, with Focus on iNKT Cell Therapies - Nasdaq

May 15, 2025

Palvella Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update - The Manila Times

May 15, 2025

MiNK Therapeutics Reports Q1 2025 Results and Highlights Clinical & Strategic Progress - GlobeNewswire

May 15, 2025

May 11, 2025

MiNK Therapeutics to Announce Q1 2025 Financial Results and Host Conference Call on May 15th - Nasdaq

May 05, 2025

MiNK Therapeutics to Provide Corporate Update and First Quarter 2025 Financial Report - GlobeNewswire

May 05, 2025

Geode Capital Management LLC Lowers Stock Position in MiNK Therapeutics, Inc. (NASDAQ:INKT) - Defense World

May 05, 2025

Apr 23, 2025

Learn to Evaluate (INKT) using the Charts - news.stocktradersdaily.com

Apr 23, 2025

Apr 19, 2025

Comparing Atyr PHARMA (NASDAQ:ATYR) and MiNK Therapeutics (NASDAQ:INKT) - Defense World

Apr 19, 2025

Apr 15, 2025

ImmunityBio Announces FDA Submissions of Supplemental BLA for NMIBC Papillary Disease and for Expanded Access of ANKTIVA® to Treat Lymphopenia - Business Wire

Apr 15, 2025

Apr 13, 2025

LIfT BioSciences appoints new CSO - Bdaily

Apr 13, 2025

Apr 07, 2025

LIfT BioSciences Appoints Mark A. Exley as Chief Scientific Officer - EIN News

Apr 07, 2025

ImmunityBio to Host Key Opinion Leader and Investor Meeting to Provide Updates on Clinical Programs and ANKTIVA Commercial Launch - Business Wire

Apr 07, 2025

Apr 06, 2025

(INKT) Trading Report - news.stocktradersdaily.com

Apr 06, 2025

Mar 30, 2025

Reviewing MiNK Therapeutics (NASDAQ:INKT) & Creative Medical Technology (NASDAQ:CELZ) - The AM Reporter

Mar 30, 2025

Mar 22, 2025

HC Wainwright Issues Negative Forecast for INKT Earnings - Defense World

Mar 22, 2025

What is William Blair’s Forecast for INKT Q1 Earnings? - Defense World

Mar 22, 2025

Mar 21, 2025

What is William Blair’s Estimate for INKT Q1 Earnings? - Defense World

Mar 21, 2025

Mar 19, 2025

MiNK Therapeutics, Inc. (NASDAQ:INKT) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 19, 2025

MiNK Therapeutics (NASDAQ:INKT) Given Buy Rating at HC Wainwright - Defense World

Mar 19, 2025